Indication
For treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who have relapsed within 12 months from completion of, or are refractory to, first line chemoimmunotherapy.
Medicine details
- Medicine name:
- lisocabtagene maraleucel (Breyanzi)
- SMC ID:
- SMC2909
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 01 September 2026